论文部分内容阅读
目的观察拉米夫定联合阿德福韦酯治疗慢性乙型肝炎的临床疗效。方法选取我院2011年4月至2013年4月收治的68例慢性乙型肝炎患者作为研究对象,随机分为两组,对照组单用拉米夫定治疗,观察组应用拉米夫定联合阿德福韦酯治疗,比较两组患者的治疗效果。结果治疗6个月时,两组患者的各项指标比较均不具有显著性差异,P>0.05;治疗12个月时,两组患者的HBeAg转阴率及HBeAg血清学转换比较,差异无统计学意义(P>0.05);但观察组的HBV-DNA拷贝量(<500copies/ml、<1000copies/ml)、ALT复常率,均显著高于对照组,P<0.05,差异有统计学意义。结论在慢性乙型肝炎的临床治疗中,与单用拉米夫定相比,拉米夫定联合阿德福韦酯治疗效果更为显著,且无不良反应,具有重要的推广应用价值。
Objective To observe the clinical efficacy of lamivudine combined with adefovir dipivoxil in the treatment of chronic hepatitis B. Methods Sixty-eight patients with chronic hepatitis B who were admitted to our hospital from April 2011 to April 2013 were randomly divided into two groups. The control group was treated with lamivudine alone. The observation group was treated with lamivudine Adefovir dipivoxil treatment, the treatment effect of two groups of patients were compared. Results At 6 months of treatment, there was no significant difference in each index between the two groups (P> 0.05). There was no significant difference in HBeAg negative rate and HBeAg seroconversion between the two groups at 12 months (P> 0.05). However, the HBV DNA copy number (<500copies / ml, <1000copies / ml) and ALT normalization rate in the observation group were significantly higher than those in the control group, P <0.05, the difference was statistically significant . Conclusions In the clinical treatment of chronic hepatitis B, lamivudine and adefovir dipivoxil are more effective than lamivudine alone in the treatment of chronic hepatitis B, and have no adverse reactions, which is of great value in popularization and application.